# Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)

> **NCT03456401** · PHASE2 · TERMINATED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 18 (actual)

## Conditions studied

- Renal Cancer Cell

## Interventions

- **DRUG:** Sorafenib or Sunitinib

## Key facts

- **NCT ID:** NCT03456401
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2017-11-08
- **Final completion:** 2017-11-08
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** availability of new and more promising therapeutic agents than expected in the experimentation in question
- **Last updated:** 2018-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03456401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03456401, "Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03456401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*